8-K
KORU Medical Systems, Inc. (KRMD)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the SecuritiesExchange Act of 1934
Date of Report (Date of earliest event reported) March 12, 2026
KORU Medical Systems, Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 0-12305 | 13-3044880 |
|---|---|---|
| (State or other jurisdiction<br><br>of incorporation) | (Commission<br><br>File Number) | (IRS Employer<br><br>Identification No.) |
| 100 Corporate Drive, Mahwah, NJ | 07430 | |
| --- | --- | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code
(845) 469-2042
______________________________________________
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[_] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[_] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[_] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[_] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading symbol(s) | Name of each exchange on which registered |
|---|---|---|
| common stock, $0.01 par value | KRMD | The Nasdaq Stock Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company [_]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [_]
ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION.
(a) Public Announcement or Release.
On March 12, 2026, KORU Medical Systems, Inc. (the “Company”) issued a press release announcing its financial results for the fourth fiscal quarter and full year ended December 31, 2025 and financial guidance for the fiscal year ended December 31, 2026. The Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. A related conference call will be held on March 12, 2026 at 4:30pm Eastern Time.
KORU Medical is making reference to non-GAAP financial measures in both the press release and the conference call. Our management believes that investors’ understanding of KORU Medical’s performance is enhanced by disclosing the non-GAAP financial measures of “adjusted EBITDA” and “adjusted diluted EPS” (each as defined below) as a reasonable basis for comparison of our ongoing results of operations. KORU Medical strongly encourages investors to review its consolidated financial statements and publicly filed reports in their entirety and cautions investors that the non-GAAP measures used by KORU Medical may differ from similar measures used by other companies, even when similar terms are used to identify such measures. Non-GAAP measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. A reconciliation of GAAP to non-GAAP results is provided in the attached Exhibit 99.1 press release.
We define adjusted EBITDA as earnings (net (loss)/income) before tax benefit and allowance for the utilization of tax benefit related to deferred tax assets, interest (income)/expense, net, depreciation and amortization, reorganization charges, tax expense (refund) and stock-based compensation expense. We believe that adjusted EBITDA is used by investors and other users of our financial statements as a supplemental financial measure that, when viewed with our GAAP results and the accompanying reconciliation, we believe provides additional information that is useful to gain an understanding of the factors and trends affecting our business. We also believe the disclosure of adjusted EBITDA helps investors meaningfully evaluate and compare our cash flow generating capacity from quarter to quarter and year to year. adjusted EBITDA is used by management as a supplemental internal measure for planning and forecasting overall expectations and for evaluating actual results against such expectations.
We present adjusted diluted earnings per share (“adjusted diluted EPS”) after eliminating items that we believe are not part of our ordinary operations and affect the comparability of the periods presented. Adjusted diluted EPS includes adjustments from reported diluted earnings per share for tax benefit and allowance for the utilization of tax benefit related to deferred tax assets, depreciation and amortization, reorganization charges, tax expense (refund) and stock-based compensation expense. We believe adjustments for these items allow investors to better understand our underlying operating results and facilitate comparisons between the periods shown. Management uses adjusted diluted EPS as a supplemental internal measure for planning and forecasting overall expectations and for evaluating actual results against such expectations.
The information contained in this Item 2.02 of the Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such filing.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.
(d) Exhibits.
| Exhibit No. | Description |
|---|---|
| 99.1 | Press Release, dated March 12, 2026 |
| 104 | Cover Page Interactive Data File (embedded within the inline XBRL document) |
- 2 -
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| KORU Medical Systems, Inc.<br><br>(Registrant) | ||
|---|---|---|
| Date: March 12, 2026 | By: | /s/ Linda Tharby |
| Linda Tharby<br><br>President and Chief Executive Officer |
- 3 -
EXHIBIT 99.1
KORU Medical Systems Announces +20% FourthQuarter and Full Year 2025 Revenue Growth,Positive Adjusted EBITDA and Initiates Full Year 2026 Guidance
MAHWAH, NJ – March 12, 2026 – KORUMedical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the fourth quarter and full year ended December 31, 2025. The Company also initiated guidance for the full year 2026.
Recent Highlights
| ● | Fourth quarter 2025 net revenues grew 23% to $10.9 million; Full year 2025 net revenues grew 22% to $41.1 million |
|---|---|
| ● | Full year 2025 gross profit grew 20% to $25.6 million with gross margin of 62.3% |
| ● | Full year 2025 net loss of ($2.6) million, a 57% improvement over the prior year and a 124% increase in positive adjusted EBITDA to $0.6 million |
| ● | Ending cash balance of $8.9 million, representing annual cash usage of $0.7 million, a 63% improvement versus the prior year |
| ● | Received 510(k) clearance for UCB RYSTIGGO®, further expanding the KORU Medical platform beyond Ig into broader therapeutic indications |
| ● | Announcing Freedom60® EU MDR certification with prefilled syringe compatibility |
| ● | Announcing an expanded development pipeline with two new pharmaceutical collaborations, including a Phase III nephrology molecule and a multi-indication drug in a Phase I trial |
| ● | Initiating 2026 guidance to include net revenues of $47.5 - $50.0 million, representing growth of 15 – 22%; gross margin of 61% - 63%; positive adjusted EBITDA and positive cash flow for the full year 2026 |
“Our fourth quarter and full year performance reflect the meaningful progress we have made building a stronger, more scalable business positioned to meet the evolving needs of the subcutaneous infusion market,” said Linda Tharby, President and CEO of KORU Medical. “Demand for immunoglobulin therapy remains robust, supporting continued growth in our recurring patient base, and we continue to gain momentum with International Core expansion. At the same time, our 510(k) filings and clearances are broadening our platform beyond Ig and into new therapeutic areas, further expanding our patient base. We enter 2026 with a proven ability to execute on our strategy, a compelling set of additional growth opportunities, and a continued commitment to shareholder value generation.”
2025 Fourth Quarter Financial Results
| Three Months Ended December 31, | Change from Prior Year | % of Net Revenues | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 2024 | % | 2025 | 2024 | ||||||
| Net Revenues | ||||||||||
| Domestic Core | $ | 7,844,822 | $ | 6,657,182 | 17.8% | 72.0% | 75.3% | |||
| International Core | 2,576,886 | 1,504,108 | 71.3% | 23.7% | 17.0% | |||||
| Total Core | 10,421,708 | 8,161,291 | 27.7% | 95.7% | 92.3% | |||||
| Pharma Services and Clinical Trials | 473,620 | 677,309 | ) | (30.1% | ) | 4.3% | 7.7% | |||
| Total | $ | 10,895,328 | $ | 8,838,600 | 23.3% | 100% | 100% |
All values are in US Dollars.
Total net revenues increased $2.1 million, or 23.3%, to $10.9 million for the fourth quarter of 2025. Domestic core growth of 17.8% was primarily due to subcutaneous immunoglobulin (SCIg) market growth driven by new patient starts and market share gains. International core growth of 71.3% was primarily due to increased penetration in established markets and subcutaneous immunoglobulin (SCIg) market growth driven by new patient starts. PST net revenues for the fourth quarter of 2025 were $0.5 million, a decrease of 30.1% over the prior year period, primarily driven by lower NRE collaboration revenue resulting from the timing of project milestones.
Gross profit increased $1.3 million, or 22.6%, to $6.8 million for the fourth quarter of 2025, compared to the fourth quarter of 2024. Gross margin was 62.6%, a decrease of 30 basis points, compared to 62.9% in the prior year period. The decrease in gross margin was primarily driven by higher material cost and tariffs, mostly offset by customer mix resulting in higher average selling prices.
Total operating expenses increased $0.2 million, or 3.0%, to $7.4 million for the fourth quarter of 2025 primarily driven by 2024 performance-based compensation expenses.
Net loss decreased $1.1 million to $0.5 million or ($0.01) per diluted share for the fourth quarter of 2025, compared to a net loss of $1.6 million, or ($0.03) per diluted share, for the prior year period. Adjusted EBITDA for the quarter was $0.5 million, or $0.01 per diluted share versus ($0.70) million or ($0.02) per diluted share in the prior year period. A reconciliation of adjusted EBITDA and adjusted diluted EPS to the most directly comparable GAAP measures is provided at the end of this press release.
2025 Full Year Financial Results
| Years Ended December 31, | Change from Prior Year | % of Net Revenues | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 2024 | % | 2025 | 2024 | ||||||
| Net Revenues | ||||||||||
| Domestic Core | $ | 27,992,436 | $ | 25,214,613 | 11.0% | 68.1% | 74.9% | |||
| International Core | 10,881,183 | 6,043,979 | 80.0% | 26.5% | 18.0% | |||||
| Total Core | 38,873,619 | 31,258,592 | 24.4% | 94.5% | 92.9% | |||||
| Pharma Services and Clinical Trials | 2,253,747 | 2,387,871 | ) | (5.6% | ) | 5.5% | 7.1% | |||
| Total | $ | 41,127,366 | $ | 33,646,463 | 22.2% | 100% | 100% |
All values are in US Dollars.
Total net revenues increased $7.5 million, or 22.2%, to $41.1 million, for the year ended December 31, 2025, as compared with the same period last year. Domestic core growth of 11.0% was primarily attributed to subcutaneous immunoglobulin (SCIg) market growth and new account share gains. International core growth of 80.0% was primarily driven by SCIg market growth driven by new patient starts, increased penetration in several established EU markets, and entry into multiple new geographic markets. PST net revenues decreased $0.1 million, or 5.6%, driven by lower NRE collaborations revenues resulting from the timing of project milestones partially offset by higher clinical trial orders when compared to the prior year.
Gross profit increased $4.3 million, or 20.0%, to $25.6 million, in the year ended December 31, 2025, compared to the same period in 2024, driven by the increase in net revenues of $7.5 million partially offset by an increase in manufacturing costs. Gross margin decreased to 62.3% in the year ended 2025 compared to 63.4% for the year ended 2024, primarily driven by higher materials costs, tariff-related charges, and geographic sales mix from outside the United States, partially offset by higher average selling prices in the US market.
Total operating expenses increased $0.8 million, or 2.9%, to $28.6 million in the year ended December 31, 2025 compared to $27.8 million from the same period last year driven primarily by compensation and legal fees.
Net loss decreased $3.4 million to $2.6 million or ($0.06) per diluted share for the year ended December 31, 2025, compared to a net loss of $6.1 million, or ($0.13) per diluted share, for the prior year period, driven by higher gross profit of $4.3 million, partially offset by an increase in operating expense of $0.8 million. Adjusted EBITDA for the full year was $0.6 million, or $0.01 per diluted share versus ($2.5) million or ($0.06) per diluted share in the prior year period. A reconciliation of adjusted EBITDA and adjusted diluted EPS to the most directly comparable GAAP measures is provided at the end of this press release. Cash and cash equivalents were $8.9 million as of December 31, 2025, reflecting cash generation of $0.4 million for fourth quarter of 2025 and cash usage of $0.7 million for the full year 2025.
2026 Guidance
KORU Medical expects:
| ● | Full year 2026 net revenues between $47.5 - $50.0 million representing growth of 15% - 22% |
|---|---|
| ● | Full year 2026 gross margin between 61 - 63% |
| ● | Positive adjusted EBITDA and positive cash flow for the full year 2026 |
- 2 -
Conference Call and Webcast Details
The Company will host a live conference call and webcast to discuss these results and provide a corporate update on Thursday, March 12, 2026, at 4:30 PM ET.
To participate in the call, please dial (877) 407-0784 (domestic) or (201) 689-8560 (international). The live webcast will be available on the IR Calendar on the News/Events page of the Investors section of KORU Medical’s website.
Non-GAAP Measures
This press release includes the non-GAAP financial measures “adjusted diluted EPS” and “adjusted EBITDA” that are not in accordance with, nor an alternate to, generally accepted accounting principles and may be different from non-GAAP measures used by other companies. These non-GAAP measures are not based on any comprehensive set of accounting rules or principles. Non-GAAP financial measures should not be considered a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. They are limited in value because they exclude charges that have a material effect on KORU Medical’s reported results and, therefore, should not be relied upon as the sole financial measures to evaluate the Company’s financial results. Non-GAAP financial measures are meant to supplement, and to be viewed in conjunction with GAAP financial results. Reconciliations of the Company’s non-GAAP measures are included at the end of this press release.
About KORU Medical Systems
KORU Medical Systems develops, manufactures, and commercializes innovative and patient-centric large volume subcutaneous infusion solutions that improve quality of life for patients around the world. The Freedom Syringe Infusion System (the “Freedom System”) currently includes the Freedom60^®^ and FreedomEDGE^®^ Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HigH-Flo Subcutaneous Safety Needle Sets™. The Freedom System, which received its first FDA clearance in 1994, is used for self-administration in the home by the patient and/or delivery in an ambulatory infusion center by a healthcare professional. Through its Pharma Service and Clinical Trials business, KORU Medical provides products for use by biopharmaceutical companies in feasibility/clinical trials during the drug development process and, as needed, is capable of customizing the Freedom System for clinical and commercial use across multiple drug categories. For more information, please visit www.korumedical.com.
Forward-looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. All statements that are not historical fact are forward-looking statements, including, but not limited to, financial guidance and expected operating performance for fiscal 2026. Forward-looking statements discuss the Company’s current expectations and projections relating to its financial position, results of operations, plans, objectives, future performance, and business. Forward-looking statements can be identified by words such as “guidance”, “expect” and “will”. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties that could cause actual results to differ from the results predicted include, among others, uncertainties associated with SCIg market growth, prefilled syringe penetration, plasma supply, clinical trial activity and success, approval and commercialization of new drug indications, the shift to increased healthcare delivery in the home, new patient diagnoses, customer ordering patterns, global and regional instability, innovation and competition, labor and supply price increases, inflationary impacts, labor supply, and those risks and uncertainties included under the captions “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, which is on file with the SEC and available on our website at www.korumedical.com/investors and on the SEC website at www.sec.gov. All information provided in this release and in the attachments is as of March 12, 2026. Undue reliance should not be placed on the forward-looking statements in this press release, which are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law.
Investor Contact:
Louisa Smith
investor@korumedical.com
- 3 -
KORU MEDICAL SYSTEMS, INC.
BALANCE SHEETS
| December 31, | |||||
|---|---|---|---|---|---|
| 2024 | |||||
| ASSETS | |||||
| CURRENT ASSETS | |||||
| Cash and cash equivalents | 8,872,212 | $ | 9,580,947 | ||
| Accounts receivable, net | 6,209,950 | 5,720,750 | |||
| Inventory, net | 3,678,131 | 2,803,669 | |||
| Other receivables | 319,955 | 277,193 | |||
| Prepaid expenses and other current assets | 908,542 | 749,851 | |||
| TOTAL CURRENT ASSETS | 19,988,790 | 19,132,410 | |||
| Property and equipment, net | 4,471,386 | 4,290,515 | |||
| Intangible assets, net of accumulated amortization of 527,949 and 458,538 at December 31, 2025 and December 31, 2024, respectively | 684,841 | 730,279 | |||
| Operating lease right-of-use assets | 2,956,192 | 2,966,341 | |||
| Other assets | 98,970 | 98,970 | |||
| TOTAL ASSETS | 28,200,179 | $ | 27,218,515 | ||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||
| CURRENT LIABILITIES | |||||
| Accounts payable | 2,267,473 | $ | 1,649,969 | ||
| Accrued expenses | 4,828,830 | 3,924,184 | |||
| Note payable | — | 271,152 | |||
| Other liabilities | 27,722 | 29,269 | |||
| Accrued payroll and related taxes | 531,972 | 811,401 | |||
| Finance lease liability | 124,913 | 115,587 | |||
| Operating lease liability | 413,448 | 400,258 | |||
| TOTAL CURRENT LIABILITIES | 8,194,358 | 7,201,820 | |||
| Finance lease liability, net current portion | 78,675 | 202,613 | |||
| Operating lease liability, net of current portion | 2,879,224 | 3,000,403 | |||
| TOTAL LIABILITIES | 11,152,257 | 10,404,836 | |||
| Commitments and contingencies (Refer to Note 9) | |||||
| STOCKHOLDERS’ EQUITY | |||||
| Common stock, 0.01 par value, 75,000,000 shares authorized, 49,790,934 and 49,377,617 shares issued; 46,370,432 and 45,957,115 shares outstanding at December 31, 2025, and December 31, 2024, respectively | 497,909 | 493,776 | |||
| Additional paid-in capital | 52,449,339 | 49,581,303 | |||
| Treasury stock, 3,438,526 and 3,438,526 shares at December 31, 2025 and December 31, 2024, respectively, at cost | (3,882,494 | ) | (3,882,494 | ) | |
| Accumulated Deficit | (32,016,832 | ) | (29,378,906 | ) | |
| TOTAL STOCKHOLDERS’ EQUITY | 17,047,922 | 16,813,679 | |||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | 28,200,179 | $ | 27,218,515 |
All values are in US Dollars.
- 4 -
KORU MEDICAL SYSTEMS, INC.
STATEMENTS OF OPERATIONS
| For the Years EndedDecember 31, | ||||||
|---|---|---|---|---|---|---|
| 2025 | 2024 | |||||
| NET REVENUES | $ | 41,127,366 | $ | 33,646,463 | ||
| Cost of goods sold | 15,523,287 | 12,314,605 | ||||
| Gross Profit | 25,604,079 | 21,331,858 | ||||
| OPERATING EXPENSES | ||||||
| Selling, general and administrative | 23,378,807 | 21,631,674 | ||||
| Research and development | 4,387,214 | 5,257,942 | ||||
| Depreciation and amortization | 810,500 | 888,473 | ||||
| Total Operating Expenses | 28,576,521 | 27,778,089 | ||||
| Net Operating Loss | (2,972,442 | ) | (6,446,231 | ) | ||
| Non-Operating Income/(Expense) | ||||||
| Income/(loss) on foreign currency exchange | 53,097 | (45,991 | ) | |||
| Other income/(expense) | 9,906 | (16,160 | ) | |||
| Interest income, net | 293,403 | 444,642 | ||||
| TOTAL OTHER INCOME | 356,406 | 382,491 | ||||
| LOSS BEFORE TAXES | (2,616,036 | ) | (6,063,740 | ) | ||
| Income tax expense | (21,890 | ) | (2,893 | ) | ||
| NET LOSS | $ | (2,637,926 | ) | $ | (6,066,633 | ) |
| NET LOSS PER SHARE | ||||||
| Basic | $ | (0.06 | ) | $ | (0.13 | ) |
| Diluted | $ | (0.06 | ) | $ | (0.13 | ) |
| WEIGHTED AVERAGE COMMON SHARES OUTSTANDING | ||||||
| Basic | 46,187,077 | 45,802,701 | ||||
| Diluted | 46,187,077 | 45,802,701 |
- 5 -
KORU MEDICAL SYSTEMS, INC.
STATEMENTS OF CASH FLOWS
| For the Years EndedDecember 31, | ||||||
|---|---|---|---|---|---|---|
| 2025 | 2024 | |||||
| CASH FLOWS FROM OPERATING ACTIVITIES | ||||||
| Net Loss | $ | (2,637,926 | ) | $ | (6,066,633 | ) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||
| Stock-based compensation expense and warrant expense | 2,713,539 | 2,623,920 | ||||
| Depreciation and amortization | 810,500 | 888,473 | ||||
| Loss/(Gain) on disposal of fixed assets | (6,700 | ) | 16,160 | |||
| Non-cash leasing charges | (97,840 | ) | 243,394 | |||
| Changes in operating assets and liabilities: | ||||||
| Increase in accounts receivable | (489,199 | ) | (1,675,540 | ) | ||
| Decrease/(Increase) in inventory | (874,462 | ) | 677,632 | |||
| Decrease/(Increase) in prepaid expenses and other assets | (196,682 | ) | 220,133 | |||
| Increase in accounts payable | 617,504 | 674,776 | ||||
| Increase/(Increase) in accrued payroll and related taxes | (279,429 | ) | 348,460 | |||
| Decrease in other liabilities | (1,547 | ) | (483,250 | ) | ||
| Increase in accrued expenses | 904,647 | 2,212,757 | ||||
| NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES | 462,405 | (319,718 | ) | |||
| CASH FLOWS FROM INVESTING ACTIVITIES | ||||||
| Purchases of property and equipment | (932,517 | ) | (1,297,427 | ) | ||
| Proceeds on disposals of property and equipment | 6,700 | 8,500 | ||||
| Purchases of intangible assets | (23,973 | ) | (44,115 | ) | ||
| NET CASH USED IN INVESTING ACTIVITIES | (949,790 | ) | (1,333,042 | ) | ||
| CASH FLOWS FROM FINANCING ACTIVITIES | ||||||
| Proceeds from exercise of employee stock options | 186,165 | — | ||||
| Borrowings from insurance finance indebtedness | 406,751 | 487,516 | ||||
| Payments on insurance finance indebtedness | (677,903 | ) | (530,707 | ) | ||
| Payments for taxes related to net share settlement of equity awards | (27,536 | ) | (97,379 | ) | ||
| Payments on finance lease liability, net of asset | (108,827 | ) | (107,963 | ) | ||
| NET CASH USED IN FINANCING ACTIVITIES | (221,350 | ) | (248,533 | ) | ||
| NET DECREASE IN CASH AND CASH EQUIVALENTS | (708,735 | ) | (1,901,293 | ) | ||
| CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR | 9,580,947 | 11,482,240 | ||||
| CASH AND CASH EQUIVALENTS, END OF YEAR | $ | 8,872,212 | $ | 9,580,947 | ||
| Supplemental Information | ||||||
| Cash paid during the years for: | ||||||
| Interest | $ | 55,546 | $ | 71,934 | ||
| Income taxes | $ | 14,850 | $ | — |
- 6 -
KORU MEDICAL SYSTEMS, INC.
SUPPLEMENTAL INFORMATION
(UNAUDITED)
A reconciliation of our non-GAAP measures is below:
| Three Months Ended | Twelve Months Ended | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reconciliation of GAAP Net (Loss) | December 31, | December 31, | ||||||||||
| to Non-GAAP Adjusted EBITDA: | 2025 | 2024 | 2025 | 2024 | ||||||||
| GAAP Net Loss | $ | (486,856 | ) | $ | (1,558,249 | ) | $ | (2,637,926 | ) | $ | (6,066,632 | ) |
| Tax Benefit | — | (185,542 | ) | — | (1,078,066 | ) | ||||||
| Allowance for Tax Benefit | — | 185,542 | — | 1,078,066 | ||||||||
| Reorganization Charges | — | — | — | 496,255 | ||||||||
| Depreciation and Amortization | 179,174 | 211,454 | 810,500 | 888,473 | ||||||||
| Interest Income, Net | (66,705 | ) | (80,459 | ) | (293,403 | ) | (444,642 | ) | ||||
| Tax Expense (Refund) | 4,684 | — | 21,890 | — | ||||||||
| Stock-based Compensation Expense | 862,807 | 699,789 | 2,713,539 | 2,623,920 | ||||||||
| Non-GAAP Adjusted EBITDA | $ | 493,104 | $ | (727,465 | ) | $ | 614,600 | $ | (2,502,626 | ) | ||
| Weighted average number of common shares | 46,302,746 | 45,907,001 | 46,187,077 | 45,802,701 | ||||||||
| Three Months Ended | Twelve Months Ended | |||||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Reconciliation of Reported Diluted EPS | December 31, | December 31, | ||||||||||
| to Non-GAAP Adjusted Diluted EPS: | 2025 | 2024 | 2025 | 2024 | ||||||||
| Reported Diluted Earnings Per Share | $ | (0.01 | ) | $ | (0.03 | ) | $ | (0.6 | ) | $ | (0.13 | ) |
| Tax Benefit | — | — | — | — | ||||||||
| Allowance for Tax Benefit | — | — | — | — | ||||||||
| Reorganization Charges | — | — | — | 0.01 | ||||||||
| Depreciation and Amortization | — | — | 0.02 | 0.02 | ||||||||
| Interest Income, Net | — | — | (0.01 | ) | (0.01 | ) | ||||||
| Tax Expense (Refund) | — | — | — | — | ||||||||
| Stock-based Compensation Expense | 0.02 | 0.01 | 0.06 | 0.06 | ||||||||
| Non-GAAP Adjusted Diluted Earnings Per Share | $ | 0.01 | $ | (0.02 | ) | $ | 0.01 | $ | (0.06 | ) |
*Numbers presented are rounded to thenearest whole cent
Allowance for nonrealization of deferred tax assets(DTA). We have excluded the effect of recording a full valuation allowance on our deferred tax assets in the fourth quarter ended 2024 in the amount of $0.2 million and $1.1 million for the full year ended 2024.
Reorganization Charges. We have excluded the effect of reorganization charges in calculating our non-GAAP measures. In 2024 we incurred severance expenses related to the reorganization of the leadership team, which we would not have otherwise incurred in periods presented as part of continuing operations.
Stock-based Compensation Expense. We have excluded the effect of stock-based compensation expense in calculating our non-GAAP measures. We record non-cash compensation expenses related to grants of equity-based awards for executives, employees, consultants, and directors. Depending upon the size, timing and the terms of the grants, the non-cash compensation expense may vary significantly but is expected to recur in future periods.
- 7 -